Acute respiratory distress syndrome (ARDS) is characterized by arterial hypoxemia secondary to protein-rich pulmonary edema associated with acute inflammation and loss of aerated lung volume [1, 2] . ARDS also involves injury to the pulmonary circulation that is associated with pulmonary hypertension and an elevation in pulmonary dead space [1, 2] . The pulmonary circulation is involved at different stages of ARDS with progression of the clinical syndrome. First, injury to the lung microcirculation causes an increase in lung vascular permeability which initiates the accumulation of pulmonary edema. Second, intravascular microthrombi can develop from an imbalance between procoagulant and fibrinolytic activity in the presence of acute inflammation and endothelial injury. Third, the marked reduction in functional residual capacity (FRC) can increase pulmonary vascular resistance (PVR). Fourth, positive pressure ventilation can induce high lung volume in some lung regions and compress alveolar vessels, resulting in increased PVR. The resulting higher regional FRC can also increase PVR. Fifth, hypoxic pulmonary vasoconstriction can further increase PVR. All these of mechanisms can contribute to an elevation in PVR that can occur within 48 h after the onset of ARDS, as demonstrated many years ago [3] and also more recently [4, 5] . The elevation in PVR may also be exacerbated by hypercapnia and acidosis. These mechanisms are summarized in Fig. 1 .
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An elevation in PVR has long been recognized as a predictor of poor prognosis in ARDS. Under normal conditions, the right ventricle (RV) pumps against a low resistance pulmonary circulation, but in the presence of an acute increase in afterload from a rise in PVR, the RV attempts to compensate by increasing end-systolic and end-diastolic volumes. If the increase in afterload is substantial, impairment of RV systolic function and interventricular septal kinetics results in a reduction in cardiac output and acute core pulmonale (ACP) with RV failure and shock. Before the era of lung protective ventilation, the incidence of ACP from elevated PVR in ARDS was as high as 60 % [6] .
In a recent article in Intensive Care Medicine, Mekontso-Dessap and colleagues [7] report the results of a study of 752 moderate to severe ARDS patients (ratio of partial pressure arterial oxygen and fraction of inspired oxygen: PaO 2 /FiO 2 \200 mmHg) designed (1) to determine the incidence of ACP, (2) to test a clinical score to predict the presence of ACP and (3) to determine the association of ACP with mortality. The diagnosis of ACP was determined by transesophageal echocardiography (TEE) and defined by septal dyskinesia with a dilated RV, end-diastolic RV/left ventricle area ratio of [0.6, and a score of [1 for severe ACP. Overall, ACP developed in 22 % of the patients. The investigators created and tested an ACP predictive clinical risk score. There were 502 patients assigned to the derivation cohort and 250 patients to the validation cohort. The four-point score (odds ratio of [2) has four components: (1) What can we learn from this study in the era of lung protective ventilation? First, although ACP is less common than in the past, a 22 % incidence is still substantial in patients with moderate to severe ARDS. The proposed clinical score may assist physicians in their decisionmaking on whether or not to perform a TEE to diagnose ACP, although we favor using a score of 4 when the incidence would be approximately 75 %. If there were a more specific therapy to apply to patients with ACP, then a TEE would be indicated even if the predictive score were lower. Since TEE is invasive, most intensivists are not skilled in the use of TEE, and TEE is contraindicated in some patients, the incorporation of TEE into regular clinical practice is difficult. Alternatively, transthoracic echocardiography (TTE) is non-invasive and practical to use, but the specific criteria for diagnosing ACP cannot be achieved in most patients with TTE.
What should intensivists do to minimize the risk of developing ACP? First, it should be emphasized that the incidence of ACP has already be reduced through the use of lung protective ventilation in the clinical setting of lower tidal volumes and reduced plateau airway pressure. It is possible that minimizing end-inspiratory lung volume and recruiting the lung to maintain regional FRC via an adequate combination of tidal volume and positive endexpiratory pressure (PEEP) to promote a driving pressure of \18 cmH 2 O would result in a further reduction of ACP, but a prospective trial is needed to test this hypothesis. Inhaled nitric oxide, a selective pulmonary vasodilator, has been used to reduce PVR and improve oxygenation [8] . However, no benefit on mortality has been found in several trials [9] , albeit these trials were completed before the current practice of lung protective ventilation for ARDS (low tidal volume [10] , prone position [11] , neuromuscular blockade [12] ).
When clinicians are confronted with ACP, hemodynamic support with intravenous fluids and vaosopressors is needed. Treatment with norepinephrine or dobutamine can increase RV contractility. Enhancing preload with a fluid challenge can also be considered. One strategy is to assess the preload dependence of the cardiac output, which requires continuous monitoring (pulmonary artery catheter or the Picco device). If preload-dependence is present, fluid removal should be discontinued, and intravenous fluids should be administered. In the absence of preload dependence, fluids should be removed under the control of preload-dependence assessment. Other strategies include prone positioning and lowering of the PEEP, or further reduction of tidal volume associated with extracorporeal CO 2 removal. Prone positioning may be useful because it allows a reduction in PEEP, thereby increasing oxygenation and FRC by promoting lung recruitment, as previously proposed [13] . However, these strategies for treating ACP have not yet been tested prospectively. In summary, the study by Mekontso-Dessap et al. [7] provides new information on the incidence of ACP (22 %) in moderate to severe ARDS in the era of lung protective ventilation. These authors report a significant association of severe ACP with higher mortality and propose a four-point clinical score that may have value for assessing the benefit (or not) of TEE to diagnose ACP in ARDS patients. More studies are needed to determine the efficacy of ventilator strategies (including prone positioning) and new pharmacologic agents to attenuate the incidence and severity of ACP in ARDS.
